Terms: = Leukemia AND MEN1, ENSG00000133895, 4221 AND Treatment
12 results:
1. Clinically Defined Mutations in
Duan S; Sheriff S; Elvis-Offiah UB; Witten BL; Sawyer TW; Sundaresan S; Cierpicki T; Grembecka J; Merchant JL
Cancer Res Commun; 2023 Jul; 3(7):1318-1334. PubMed ID: 37492626
[TBL] [Abstract] [Full Text] [Related]
2. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for leukemia and Cancers.
Shi Q; Xu M; Kang Z; Zhang M; Luo Y
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
[TBL] [Abstract] [Full Text] [Related]
3. Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021).
Bai H; Zhang SQ; Lei H; Wang F; Ma M; Xin M
Expert Opin Ther Pat; 2022 May; 32(5):507-522. PubMed ID: 35202550
[TBL] [Abstract] [Full Text] [Related]
4. Therapeutic implications of menin inhibition in acute leukemias.
Issa GC; Ravandi F; DiNardo CD; Jabbour E; Kantarjian HM; Andreeff M
Leukemia; 2021 Sep; 35(9):2482-2495. PubMed ID: 34131281
[TBL] [Abstract] [Full Text] [Related]
5. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract] [Full Text] [Related]
6. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged leukemia.
Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
[TBL] [Abstract] [Full Text] [Related]
7. How to effectively treat acute leukemia patients bearing MLL-rearrangements ?
Steinhilber D; Marschalek R
Biochem Pharmacol; 2018 Jan; 147():183-190. PubMed ID: 28943239
[TBL] [Abstract] [Full Text] [Related]
8. A Review of the Scaffold Protein Menin and its Role in Hepatobiliary Pathology.
Ehrlich L; Hall C; Meng F; Lairmore T; Alpini G; Glaser S
Gene Expr; 2017 Jul; 17(3):251-263. PubMed ID: 28485270
[TBL] [Abstract] [Full Text] [Related]
9. MLL leukemia and future treatment strategies.
Marschalek R
Arch Pharm (Weinheim); 2015 Apr; 348(4):221-8. PubMed ID: 25740345
[TBL] [Abstract] [Full Text] [Related]
10. Menin expression is regulated by transforming growth factor beta signaling in leukemia cells.
Zhang H; Liu ZG; Hua XX
Chin Med J (Engl); 2011 May; 124(10):1556-62. PubMed ID: 21740816
[TBL] [Abstract] [Full Text] [Related]
11. Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue.
Horiguchi K; Yamada M; Satoh T; Hashimoto K; Hirato J; Tosaka M; Yamada S; Mori M
Clin Cancer Res; 2009 Apr; 15(8):2620-9. PubMed ID: 19318494
[TBL] [Abstract] [Full Text] [Related]
12. Antiviral activity of 3-deazaguanine, 3-deazaguanosine, and 3-deazaguanylic acid.
Allen LB; Huffman JH; Dan Cook P; Meyer RB; Robins RK; Sidwell RW
Antimicrob Agents Chemother; 1977 Jul; 12(1):114-9. PubMed ID: 196546
[TBL] [Abstract] [Full Text] [Related]
